Malaria Prophylaxis for Kenya and Tanzania
For healthy adults traveling to Kenya and Tanzania, mefloquine is the most effective chemoprophylaxis option, with atovaquone-proguanil as an excellent alternative, while chloroquine plus proguanil provides substantial but inferior protection.
Primary Recommendation
Kenya and Tanzania are high-risk areas with widespread chloroquine-resistant Plasmodium falciparum malaria. Based on the available evidence:
First-Line Options:
Mefloquine: Provides superior protection in sub-Saharan Africa 1, 2. In travelers to Kenya specifically, mefloquine demonstrated an odds ratio of 0.055 (95% CI 0.019-0.16), meaning it reduced malaria risk by approximately 94% 2. This represents the highest level of protection available.
Atovaquone-Proguanil: While not extensively covered in the older guidelines provided, contemporary expert opinion strongly favors this as first choice for short-term travel (2 weeks) with 91.67% of European experts recommending it 3. It has fewer neuropsychiatric side effects than mefloquine.
Second-Line Option:
- Chloroquine 300 mg base weekly PLUS Proguanil 200 mg daily: This combination provides "substantial protection, though less than that provided by mefloquine" 1. In Kenya travelers, this combination showed an odds ratio of 0.128 (95% CI 0.039-0.419), representing approximately 87% protection 2. However, efficacy is "limited in sub-Saharan Africa" 1.
Dosing and Timing
Critical compliance factors (most malaria deaths occur in non-compliant travelers 1):
- Start chemoprophylaxis one week before departure to establish the habit and identify intolerance early 1
- Continue for four weeks after returning 1
- Take medications consistently without missing doses
Specific dosing:
- Mefloquine: Standard adult dose (typically 250 mg weekly, though exact dose not specified in guidelines)
- Chloroquine: 300 mg base weekly
- Proguanil: 200 mg daily
Contraindications and Special Considerations
Mefloquine should NOT be used in:
- History of convulsions, epilepsy, or serious psychiatric disorder 1
- Liver impairment 1
- Pregnancy 4
- Children <15 kg 4
- Those using beta blockers or drugs affecting cardiac conduction 4
- Travelers requiring fine coordination (e.g., pilots) 4
Neuropsychiatric effects: Occur in 70% of cases within the first three doses if they occur at all. Severe effects reported in 0.01-0.1% 1. These include anxiety, depression, sleep disturbances, nightmares, hallucinations, and rarely psychotic attacks or convulsions 1.
Doxycycline (Alternative):
- Useful as second-line for those unable to take mefloquine 1
- Contraindicated: Pregnancy, children <8 years 4
- Side effects: Photosensitivity (avoid sun exposure), monilial vaginitis, GI upset 4
- Take in evening with food to minimize side effects 4
Mosquito Bite Prevention (Essential Adjunct)
All travelers must combine chemoprophylaxis with bite prevention 1:
- Permethrin-impregnated bed nets (0.2 g/m² every 6 months, tucked under mattress) 1
- DEET-containing repellents on exposed skin (follow manufacturer's dosing) 1
- Long-sleeved clothing and long trousers after sunset 1
- Pyrethroid vaporizers or mosquito coils overnight 1
- Screened rooms when possible 1
Common Pitfalls
- Inappropriate medical advice: 87.5% of inadequate prophylaxis cases resulted from poor medical guidance 2
- Prophylaxis refusal: 58.1% of travelers refused prophylaxis despite correct advice 2
- Inadequate duration: Continue for full 4 weeks post-travel; breakthroughs occurred as early as 7 weeks into travel 5
- Non-compliance: The single biggest cause of malaria deaths in travelers 1
Evidence Quality Note
The guidelines provided are from 1990-1995 [1-4], which is significantly outdated. However, the fundamental principles remain valid: Kenya and Tanzania have high-risk, chloroquine-resistant malaria requiring robust chemoprophylaxis. More recent research 3, 2 confirms mefloquine's efficacy and shows expert preference shifting toward atovaquone-proguanil for short-term travel, though mefloquine remains highly effective and is preferred for longer durations (>2 months) and in resource-limited situations 3.
The choice between mefloquine and atovaquone-proguanil should be based on: trip duration (atovaquone-proguanil for <2 months, mefloquine for longer), contraindications, cost considerations, and patient preference regarding side effect profiles.